These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33741855)

  • 1. 18F-FAZA PET/CT in pretreatment assessment of hypoxic status in high-grade glioma: correlation with hypoxia immunohistochemical biomarkers.
    Mapelli P; Callea M; Fallanca F; Castellano A; Bailo M; Scifo P; Bettinardi V; Conte GM; Monterisi C; Rancoita PMV; Incerti E; Vuozzo M; Gianolli L; Terreni M; Anzalone N; Picchio M
    Nucl Med Commun; 2021 Jul; 42(7):763-771. PubMed ID: 33741855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry.
    Mapelli P; Bettinardi V; Fallanca F; Incerti E; Compierchio A; Rossetti F; Coliva A; Savi A; Doglioni C; Negri G; Gianolli L; Picchio M
    Curr Radiopharm; 2018; 11(1):50-57. PubMed ID: 29119942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FAZA PET/CT Hypoxia Imaging of High-Grade Glioma Before and After Radiotherapy.
    Mapelli P; Zerbetto F; Incerti E; Conte GM; Bettinardi V; Fallanca F; Anzalone N; Di Muzio N; Gianolli L; Picchio M
    Clin Nucl Med; 2017 Dec; 42(12):e525-e526. PubMed ID: 29035992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
    Bekaert L; Valable S; Lechapt-Zalcman E; Ponte K; Collet S; Constans JM; Levallet G; Bordji K; Petit E; Branger P; Emery E; Manrique A; Barré L; Bernaudin M; Guillamo JS
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1383-1392. PubMed ID: 28315948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FAZA PET imaging in tumor hypoxia: A focus on high-grade glioma.
    Mapelli P; Picchio M
    Int J Biol Markers; 2020 Feb; 35(1_suppl):42-46. PubMed ID: 32079461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry.
    Bruine de Bruin L; Bollineni VR; Wachters JE; Schuuring E; van Hemel BM; van der Wal JE; Slagter-Menkema L; de Bock GH; Steenbakkers RJ; Langendijk JA; Pruim J; van der Laan BF; Halmos GB
    Radiother Oncol; 2015 Oct; 117(1):106-12. PubMed ID: 26250803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia and Amino Acid Imaging of High-Grade Glioma: 18F-FAZA PET/CT and 11C-Methionine PET/MRI.
    Mapelli P; Fallanca F; Scifo P; Barbera M; Castellano A; Bettinardi V; Incerti E; Gianolli L; Anzalone N; Picchio M
    Clin Nucl Med; 2020 Jun; 45(6):e290-e293. PubMed ID: 32332306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques.
    Garcia-Parra R; Wood D; Shah RB; Siddiqui J; Hussain H; Park H; Desmond T; Meyer C; Piert M
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1816-23. PubMed ID: 21833840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
    Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Nakajo M; Jinguji M; Tani A; Kajiya Y; Nandate T; Kitazano I; Yoshiura T
    Mol Imaging Biol; 2020 Dec; 22(6):1609-1620. PubMed ID: 32651718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
    Gammon ST; Pisaneschi F; Bandi ML; Smith MG; Sun Y; Rao Y; Muller F; Wong F; De Groot J; Ackroyd J; Mawlawi O; Davies MA; Gopal YNV; Di Francesco ME; Marszalek JR; Dewhirst M; Piwnica-Worms D
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three
    Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
    Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial.
    Capitanio U; Pepe G; Incerti E; Larcher A; Trevisani F; Lucianò R; Mapelli P; Bettinardi V; Monterisi C; Necchi A; Cascinu S; Bernardi R; Bertini R; Doglioni C; Gianolli L; Salonia A; Picchio M; Montorsi F
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):554-560. PubMed ID: 32638098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
    Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
    Metellus P; Colin C; Taieb D; Guedj E; Nanni-Metellus I; de Paula AM; Colavolpe C; Fuentes S; Dufour H; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    J Neurooncol; 2011 Dec; 105(3):591-600. PubMed ID: 21643985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
    Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
    Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
    Kawai N; Lin W; Cao WD; Ogawa D; Miyake K; Haba R; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1870-8. PubMed ID: 24781871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy.
    Bittner MI; Wiedenmann N; Bucher S; Hentschel M; Mix M; Rücker G; Weber WA; Meyer PT; Werner M; Grosu AL; Kayser G
    Acta Oncol; 2016 Nov; 55(11):1299-1304. PubMed ID: 27593107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.
    Bucau M; Laurent-Bellue A; Poté N; Hentic O; Cros J; Mikail N; Rebours V; Ruszniewski P; Lebtahi R; Couvelard A
    Neuroendocrinology; 2018; 106(3):274-282. PubMed ID: 28803235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.